Patients with psoriasis are more at risk of developing cardiovascular conditions than the healthy population. The aim of this line of research is to characterise the mechanisms responsible for incrementing said risk and to evaluate if the biologic drugs developed to treat psoriasis are as effective in protecting against cardiovascular illnesses as they are against psoriasis. To do this we employ in vitro and in vivo models.